Abstract
SARS-CoV-2 remains a worldwide emergency. While vaccines have been approved and are widely administered, these are only available to adults and adolescents in Europe. Therefore, in order to mitigate the spread of more transmissible SARS-CoV-2 variants among children, the use of non-pharmaceutical interventions is still warranted. We investigate the impact of different testing strategies on the SARS-CoV-2 infection dynamics in a primary school environment, using an individual-based modelling approach. Specifically, we consider three testing strategies: 1) symptomatic isolation, where we test symptomatic individuals and isolate them when they test positive, 2) reactive screening, where a class is screened once one symptomatic individual was identified, and 3) repetitive screening, where the school in its entirety is screened on regular time intervals. Through this analysis, we demonstrate that repetitive testing strategies can significantly reduce the attack rate in schools, contrary to a reactive screening approach. Furthermore, we investigate the impact of these testing strategies on the average number of school days lost per child.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
L.W and P.J.K.L. acknowledge support from the Research Foundation Flanders (fwo.be) (postdoctoral fellowships 1234620N and 1242021N). N.H. and P.J.K.L. acknowledge support from from the European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (grant number 101003688 EpiPose project). N.H. and A.T. received funding from the European Research Council (ERC) under the European Union Horizon 2020 research and innovation programme (grant number 682540 TransMID project). N.H. acknowledge funding from the Antwerp Study Centre for Infectious Diseases (ASCID) and the chair in evidence-based vaccinology at the Methusalem-Centre of Excellence consortium VAX-IDEA. C.M. received funding from the Fondation Leon Fredericq and the Fond de investissement de recherche scientifique from the CHU of Liege. G.D. received Postdoctorate Clinical Master Specialists funding from the Fund for Scientific Research (frs-fnrs.be). We used computational resources and services provided by the Flemish Supercomputer Centre (VSC) funded by the FWO and the Flemish Government. The funding agencies had no role in study design data collection and analysis decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All results presented in this work can be produced with the code on https://github.com/AndreaTorneri/TestingStrategie
